MultifacetedProtDB - Bologna Biocomputing Group

EC number	EC number description
2.7.11.24	Transferases; Transferring phosphorus-containing groups; Protein-serine/threonine kinases; mitogen-activated protein kinase

Structure

PDB	Resolution (Å)	PDB name
1PME	2.0	STRUCTURE OF PENTA MUTANT HUMAN ERK2 MAP KINASE COMPLEXED WITH A SPECIFIC INHIBITOR OF HUMAN P38 MAP KINASE
1TVO	2.5	The structure of ERK2 in complex with a small molecule inhibitor
1WZY	2.5	Crystal structure of human ERK2 complexed with a pyrazolopyridazine derivative
2OJG	2.0	Crystal structure of ERK2 in complex with N,N-dimethyl-4-(4-phenyl-1H-pyrazol-3-yl)-1H-pyrrole-2-carboxamide
2OJI	2.6	Crystal structure of ERK2 in complex with N-benzyl-4-(4-(3-chlorophenyl)-1H-pyrazol-3-yl)-1H-pyrrole-2-carboxamide
2OJJ	2.4	Crystal structure of ERK2 in complex with (S)-N-(1-(3-chloro-4-fluorophenyl)-2-hydroxyethyl)-4-(4-(3-chlorophenyl)-1H-pyrazol-3-yl)-1H-pyrrole-2-carboxamide
2Y9Q	1.55	Crystal structure of human ERK2 complexed with a MAPK docking peptide
3D42	2.46	Crystal structure of HePTP in complex with a monophosphorylated Erk2 peptide
3D44	1.9	Crystal structure of HePTP in complex with a dually phosphorylated Erk2 peptide mimetic
3I5Z	2.2	Crystal structure of ERK2 bound to (S)-N-(2-hydroxy-1-phenylethyl)-4-(5-methyl-2-(phenylamino)pyrimidin-4-yl)-1H-pyrrole-2-carboxamide
3I60	2.5	Crystal structure of ERK2 bound to (S)-4-(2-(2-chlorophenylamino)-5-methylpyrimidin-4-yl)-N-(2-hydroxy-1-phenylethyl)-1H-pyrrole-2-carboxamide
3SA0	1.5947	Complex of ERK2 with norathyriol
3TEI	2.404	Crystal structure of human ERK2 complexed with a MAPK docking peptide
3W55	3.0	The structure of ERK2 in complex with FR148083
4FMQ	2.098	Crystal structure of human ERK2 complexed with a MAPK docking peptide
4FUX	2.2	Crystal Structure of the ERK2 complexed with E75
4FUY	2.0	Crystal Structure of the ERK2 complexed with EK2
4FV0	2.1	Crystal Structure of the ERK2 complexed with EK3
4FV1	1.99	Crystal Structure of the ERK2 complexed with EK4
4FV2	2.0	Crystal Structure of the ERK2 complexed with EK5
4FV3	2.2	Crystal Structure of the ERK2 complexed with EK6
4FV4	2.5	Crystal Structure of the ERK2 complexed with EK7
4FV5	2.4	Crystal Structure of the ERK2 complexed with EK9
4FV6	2.5	Crystal Structure of the ERK2 complexed with E57
4FV7	1.9	Crystal Structure of the ERK2 complexed with E94
4FV8	2.0	Crystal Structure of the ERK2 complexed with E63
4FV9	2.11	Crystal Structure of the ERK2 complexed with E71
4G6N	2.0	Crystal Structure of the ERK2
4G6O	2.2	Crystal Structure of the ERK2
4H3P	2.3	Crystal structure of human ERK2 complexed with a MAPK docking peptide
4H3Q	2.2	Crystal structure of human ERK2 complexed with a MAPK docking peptide
4IZ5	3.19	Structure of the complex between ERK2 phosphomimetic mutant and PEA-15
4IZ7	1.8	Structure of Non-Phosphorylated ERK2 bound to the PEA-15 Death Effector Domain
4IZA	1.93	Structure of Dually Phosphorylated ERK2 bound to the PEA-15 Death Effector Domain
4N0S	1.7992	Complex of ERK2 with caffeic acid
4NIF	2.15	Heterodimeric structure of ERK2 and RSK1
4O6E	1.95	Discovery of 5,6,7,8-tetrahydropyrido[3,4-d]pyrimidine Inhibitors of Erk2
4QP1	2.7	Crystal structure of ERK2 in complex with N-cyclohexyl-9H-purin-6-amine
4QP2	2.23	Crystal Structure of ERKs in complex with 5-chlorobenzo[d]oxazol-2-amine
4QP3	2.599	Crystal Structure of ERK2 in complex with (S)-2-((9H-purin-6-yl)amino)-3-phenylpropan-1-ol
4QP4	2.2	Crystal Structure of ERK2 in complex with N-cyclohexyl-9H-purin-6-amine
4QP6	3.1	Crystal Structure of ERK2 in complex with 5H-pyrrolo[2,3-b]pyrazine
4QP7	2.249	Crystal Structure of ERK2 in complex with 2-(1H-pyrazol-4-yl)-5H-pyrrolo[2,3-b]pyrazine
4QP8	2.446	Crystal Structure of ERK2 in complex with 2-(1H-pyrazol-4-yl)-7-(pyridin-3-yl)-5H-pyrrolo[2,3-b]pyrazine
4QP9	2.001	Crystal Structure of ERK2 in complex with 7-(1-propyl-1H-pyrazol-4-yl)-2-(pyridin-4-yl)-5H-pyrrolo[2,3-b]pyrazine
4QPA	2.85	Crystal Structure of ERK2 in complex with 7-(1-benzyl-1H-pyrazol-4-yl)-2-(pyridin-4-yl)-5H-pyrrolo[2,3-b]pyrazine
4QTA	1.45	Structure of human ERK2 in complex with SCH772984 revealing a novel inhibitor-induced binding pocket
4QTE	1.5	Structure of ERK2 in complex with VTX-11e, 4-{2-[(2-CHLORO-4-FLUOROPHENYL)AMINO]-5-METHYLPYRIMIDIN-4-YL}-N-[(1S)-1-(3-CHLOROPHENYL)-2-HYDROXYETHYL]-1H-PYRROLE-2-CARBOXAMIDE
4XJ0	2.58	Crystal structure of ERK2 in complex with an inhibitor 14K
4ZXT	2.0	Complex of ERK2 with catechol
4ZZM	1.89	Human ERK2 in complex with an irreversible inhibitor
4ZZN	1.33	Human ERK2 in complex with an inhibitor
4ZZO	1.63	Human ERK2 in complex with an irreversible inhibitor
5AX3	2.984	Crystal structure of ERK2 complexed with allosteric and ATP-competitive inhibitors.
5BUE	2.4	ERK2 complexed with N-benzylpyridone tetrahydroazaindazole
5BUI	2.12	ERK2 complexed with 2-pyridiyl tetrahydroazaindazole
5BUJ	1.85	ERK2 complexed with a N-H tetrahydroazaindazole
5BVD	1.9	Tetrahydropyrrolo-diazepenones as inhibitors of ERK2 kinase
5BVE	2.0	Tetrahydropyrrolo-diazepenones as inhibitors of ERK2 kinase
5BVF	1.9	Tetrahydropyrrolo-diazepenones as inhibitors of ERK2 kinase
5K4I	1.76	Crystal Structure of ERK2 in complex with compound 22
5LCJ	1.78	In-Gel Activity-Based Protein Profiling of a Clickable Covalent Erk 1/2 Inhibitor
5LCK	1.89	A Clickable Covalent ERK 1/2 Inhibitor
5NGU	2.74	Human Erk2 with an Erk1/2 inhibitor
5NHF	2.14	Human Erk2 with an Erk1/2 inhibitor
5NHH	1.94	Human Erk2 with an Erk1/2 inhibitor
5NHJ	2.12	Human Erk2 with an Erk1/2 inhibitor
5NHL	2.07	Human Erk2 with an Erk1/2 inhibitor
5NHO	2.24	Human Erk2 with an Erk1/2 inhibitor
5NHP	1.99	Human Erk2 with an Erk1/2 inhibitor
5NHV	2.0	Human Erk2 with an Erk1/2 inhibitor
5V60	2.18	Phospho-ERK2 bound to AMP-PCP
5V61	2.2	Phospho-ERK2 bound to bivalent inhibitor SBP2
5V62	1.9	Phospho-ERK2 bound to bivalent inhibitor SBP3
5WP1	1.4	Complex of ERK2 with 5,7-dihydroxychromone
6D5Y	2.86	Crystal structure of ERK2 G169D mutant
6DMG	2.2	A multiconformer ligand model of EK6 bound to ERK2
6G54	2.05	Crystal structure of ERK2 covalently bound to SM1-71
6G8X	1.76	Fragment-based discovery of a highly potent, orally bioavailable inhibitor which modulates the phosphorylation and catalytic activity of ERK1/2
6G91	1.8	Fragment-based discovery of a highly potent, orally bioavailable inhibitor which modulates the phosphorylation and catalytic activity of ERK1/2
6G92	1.99	Fragment-based discovery of a highly potent, orally bioavailable inhibitor which modulates the phosphorylation and catalytic activity of ERK1/2
6G93	1.67	Fragment-based discovery of a highly potent, orally bioavailable inhibitor which modulates the phosphorylation and catalytic activity of ERK1/2
6G97	1.9	Fragment-based discovery of a highly potent, orally bioavailable inhibitor which modulates the phosphorylation and catalytic activity of ERK1/2
6G9A	1.91	Fragment-based discovery of a highly potent, orally bioavailable inhibitor which modulates the phosphorylation and catalytic activity of ERK1/2
6G9D	1.8	Fragment-based discovery of a highly potent, orally bioavailable inhibitor which modulates the phosphorylation and catalytic activity of ERK1/2
6G9H	1.73	Fragment-based discovery of a highly potent, orally bioavailable inhibitor which modulates the phosphorylation and catalytic activity of ERK1/2
6G9J	1.98	Fragment-based discovery of a highly potent, orally bioavailable inhibitor which modulates the phosphorylation and catalytic activity of ERK1/2
6G9K	1.94	Fragment-based discovery of a highly potent, orally bioavailable inhibitor which modulates the phosphorylation and catalytic activity of ERK1/2
6G9M	1.86	Fragment-based discovery of a highly potent, orally bioavailable inhibitor which modulates the phosphorylation and catalytic activity of ERK1/2
6G9N	1.76	Fragment-based discovery of a highly potent, orally bioavailable inhibitor which modulates the phosphorylation and catalytic activity of ERK1/2
6GDM	1.91	Fragment-based discovery of a highly potent, orally bioavailable inhibitor which modulates the phosphorylation and catalytic activity of ERK1/2
6GDQ	1.86	Fragment-based discovery of a highly potent, orally bioavailable inhibitor which modulates the phosphorylation and catalytic activity of ERK1/2
6GE0	1.82	Fragment-based discovery of a highly potent, orally bioavailable inhibitor which modulates the phosphorylation and catalytic activity of ERK1/2
6GJB	1.82	Erk2 signalling protein
6GJD	1.58	Erk2 signalling protein
6NBS	1.9	WT ERK2 with compound 2507-8
6OPG	2.9	phosphorylated ERK2 with AMP-PNP
6OPH	2.4	phosphorylated ERK2 with GDC-0994
6OPI	3.0	phosphorylated ERK2 with SCH-CPD336
6Q7K	1.84	ERK2 mini-fragment binding
6Q7S	1.73	ERK2 mini-fragment binding
6Q7T	1.6	ERK2 mini-fragment binding
6QA1	1.58	ERK2 mini-fragment binding
6QA3	1.57	ERK2 mini-fragment binding
6QA4	1.6	ERK2 mini-fragment binding
6QAG	2.07	ERK2 mini-fragment binding
6QAH	1.58	ERK2 mini-fragment binding
6QAL	1.57	ERK2 mini-fragment binding
6QAQ	1.58	ERK2 mini-fragment binding
6QAW	1.84	ERK2 mini-fragment binding
6RQ4	1.96	Inhibitor of ERK2
6SLG	1.33	HUMAN ERK2 WITH ERK1/2 INHIBITOR, AZD0364.
7AUV	1.76	The structure of ERK2 in complex with dual inhibitor ASTX029
7E73	2.28	Crystal structure of human ERK2 mutant (Y36H)
7E75	2.481	Crystal structure of human ERK2 mutant (G37C)
7NQQ	1.943	Discovery of ASTX029, a clinical candidate which modulates the phosphorylation and catalytic activity of ERK1/2
7NQW	1.775	Discovery of ASTX029, a clinical candidate which modulates the phosphorylation and catalytic activity of ERK1/2
7NR3	1.897	Discovery of ASTX029, a clinical candidate which modulates the phosphorylation and catalytic activity of ERK1/2
7NR5	1.766	Discovery of ASTX029, a clinical candidate which modulates the phosphorylation and catalytic activity of ERK1/2
7NR8	1.627	Discovery of ASTX029, a clinical candidate which modulates the phosphorylation and catalytic activity of ERK1/2
7NR9	1.906	Discovery of ASTX029, a clinical candidate which modulates the phosphorylation and catalytic activity of ERK1/2
7OPM	2.45	Phosphorylated ERK2 in complex with ORF45
7W5O	2.35	Crystal structure of ERK2 with an allosteric inhibitor
7X4U	1.98	Crystal structure of ERK2 with an allosteric inhibitor 2
7XC1	2.09	Crystal structure of ERK2 with an allosteric inhibitor 3
8AO2	1.796	Specific covalent inhibitor (3) of ERK2
8AO3	1.778	Specific covalent inhibitor of ERK2
8AO4	1.825	Specific covalent inhibitor (5) of ERK2
8AO5	1.595	Specific covalent inhibitor (6) of ERK2
8AO6	1.811	electrophilic inhibitor (7) of ERK2
8AO7	1.61	Specific covalent inhibitor (8) of ERK2
8AO8	1.697	Specific covalent inhibitor(9) of ERK2
8AO9	1.624	Specific covalent inhibitor(10) of ERK2
8AOA	1.62	Covalent and non-covalent inhibitor of ERK2 (two sites)
8AOB	1.623	Specific covalent inhibitor(12) of ERK2
8AOC	1.62	Specific covalent inhibitor of ERK2
8AOD	1.62	Specific covalent inhibitor(14) of ERK2
8AOE	1.687	Specific covalent inhibitor(15) of ERK2
8AOF	1.615	Specific covalent inhibitor(16) of ERK2
8AOG	1.603	Non-specific covalent inhibitor(17) of ERK2
8AOH	1.6	Specific covalent inhibitor(18) of ERK2
8AOI	1.602	Specific covalent inhibitor(19) of ERK2
8AOJ	1.12	Specific covalent inhibitor of ERK2

GO term

GO ontology	GO term	GO description
Biological Process	GO:0050853	B cell receptor signaling pathway
Biological Process	GO:0060020	Bergmann glial cell differentiation
Biological Process	GO:0006974	DNA damage response
Biological Process	GO:0038127	ERBB signaling pathway
Biological Process	GO:0070371	ERK1 and ERK2 cascade
Biological Process	GO:0050852	T cell receptor signaling pathway
Biological Process	GO:0030521	androgen receptor signaling pathway
Biological Process	GO:0006915	apoptotic process
Biological Process	GO:0061308	cardiac neural crest cell development involved in heart development
Biological Process	GO:0072584	caveolin-mediated endocytosis
Biological Process	GO:0007049	cell cycle
Biological Process	GO:0007166	cell surface receptor signaling pathway
Biological Process	GO:0034198	cellular response to amino acid starvation
Biological Process	GO:0071276	cellular response to cadmium ion
Biological Process	GO:0034614	cellular response to reactive oxygen species
Biological Process	GO:0071356	cellular response to tumor necrosis factor
Biological Process	GO:0007268	chemical synaptic transmission
Biological Process	GO:0006935	chemotaxis
Biological Process	GO:0019858	cytosine metabolic process
Biological Process	GO:0060324	face development
Biological Process	GO:0008286	insulin receptor signaling pathway
Biological Process	GO:0048009	insulin-like growth factor receptor signaling pathway
Biological Process	GO:0035556	intracellular signal transduction
Biological Process	GO:0060716	labyrinthine layer blood vessel development
Biological Process	GO:0007611	learning or memory
Biological Process	GO:0031663	lipopolysaccharide-mediated signaling pathway
Biological Process	GO:0060291	long-term synaptic potentiation
Biological Process	GO:0060425	lung morphogenesis
Biological Process	GO:0033598	mammary gland epithelial cell proliferation
Biological Process	GO:0045596	negative regulation of cell differentiation
Biological Process	GO:0042473	outer ear morphogenesis
Biological Process	GO:0018105	peptidyl-serine phosphorylation
Biological Process	GO:0018107	peptidyl-threonine phosphorylation
Biological Process	GO:0010759	positive regulation of macrophage chemotaxis
Biological Process	GO:0120041	positive regulation of macrophage proliferation
Biological Process	GO:0010800	positive regulation of peptidyl-threonine phosphorylation
Biological Process	GO:0051973	positive regulation of telomerase activity
Biological Process	GO:1904355	positive regulation of telomere capping
Biological Process	GO:0032212	positive regulation of telomere maintenance via telomerase
Biological Process	GO:0050847	progesterone receptor signaling pathway
Biological Process	GO:0006468	protein phosphorylation
Biological Process	GO:0090170	regulation of Golgi inheritance
Biological Process	GO:0030641	regulation of cellular pH
Biological Process	GO:0051493	regulation of cytoskeleton organization
Biological Process	GO:2000641	regulation of early endosome to late endosome transport
Biological Process	GO:0030278	regulation of ossification
Biological Process	GO:0031647	regulation of protein stability
Biological Process	GO:0032872	regulation of stress-activated MAPK cascade
Biological Process	GO:0070849	response to epidermal growth factor
Biological Process	GO:0043330	response to exogenous dsRNA
Biological Process	GO:0035094	response to nicotine
Biological Process	GO:0007165	signal transduction
Biological Process	GO:0043401	steroid hormone mediated signaling pathway
Biological Process	GO:0051403	stress-activated MAPK cascade
Biological Process	GO:0048538	thymus development
Biological Process	GO:0030878	thyroid gland development
Biological Process	GO:0060440	trachea formation
Molecular Function	GO:0005524	ATP binding
Molecular Function	GO:0003677	DNA binding
Molecular Function	GO:0004707	MAP kinase activity
Molecular Function	GO:0004708	MAP kinase kinase activity
Molecular Function	GO:0008353	RNA polymerase II CTD heptapeptide repeat kinase activity
Molecular Function	GO:0042802	identical protein binding
Molecular Function	GO:0019902	phosphatase binding
Molecular Function	GO:0001784	phosphotyrosine residue binding
Molecular Function	GO:0106310	protein serine kinase activity
Molecular Function	GO:0004674	protein serine/threonine kinase activity
Cellular Component	GO:0005794	Golgi apparatus
Cellular Component	GO:0035578	azurophil granule lumen
Cellular Component	GO:0005901	caveola
Cellular Component	GO:0005737	cytoplasm
Cellular Component	GO:0005856	cytoskeleton
Cellular Component	GO:0005829	cytosol
Cellular Component	GO:0005769	early endosome
Cellular Component	GO:0005788	endoplasmic reticulum lumen
Cellular Component	GO:0005576	extracellular region
Cellular Component	GO:1904813	ficolin-1-rich granule lumen
Cellular Component	GO:0005925	focal adhesion
Cellular Component	GO:0005770	late endosome
Cellular Component	GO:0005815	microtubule organizing center
Cellular Component	GO:0005739	mitochondrion
Cellular Component	GO:0072686	mitotic spindle
Cellular Component	GO:0005654	nucleoplasm
Cellular Component	GO:0005634	nucleus
Cellular Component	GO:0005886	plasma membrane
Cellular Component	GO:0031143	pseudopodium
Cellular Component	GO:0045202	synapse

InterPro / Pfam

InterPro	InterPro name
IPR000719	Protein kinase domain
IPR003527	Mitogen-activated protein (MAP) kinase, conserved site
IPR008271	Serine/threonine-protein kinase, active site
IPR008349	Mitogen-activated protein (MAP) kinase, ERK1/2
IPR011009	Protein kinase-like domain superfamily
IPR017441	Protein kinase, ATP binding site

Pfam	Pfam name
PF00069	Protein kinase domain

Reactome

Reactome	Reactome Name	Node type	Reactome Root	Reactome Root Name
R-HSA-111995	phospho-PLA2 pathway	Leaf	R-HSA-162582	Signal Transduction
R-HSA-112409	RAF-independent MAPK1/3 activation	Internal node	R-HSA-162582	Signal Transduction
R-HSA-112411	MAPK1 (ERK2) activation	Leaf	R-HSA-162582	Signal Transduction
R-HSA-1181150	Signaling by NODAL	Internal node	R-HSA-1266738	Developmental Biology
R-HSA-1295596	Spry regulation of FGF signaling	Leaf	R-HSA-162582	Signal Transduction
R-HSA-1502540	Signaling by Activin	Internal node	R-HSA-162582	Signal Transduction
R-HSA-162658	Golgi Cisternae Pericentriolar Stack Reorganization	Leaf	R-HSA-1640170	Cell Cycle
R-HSA-170968	Frs2-mediated activation	Leaf	R-HSA-162582	Signal Transduction
R-HSA-198753	ERK/MAPK targets	Internal node	R-HSA-162582	Signal Transduction
R-HSA-202670	ERKs are inactivated	Leaf	R-HSA-168256	Immune System
R-HSA-2029482	Regulation of actin dynamics for phagocytic cup formation	Leaf	R-HSA-168256	Immune System
R-HSA-2173795	Downregulation of SMAD2/3:SMAD4 transcriptional activity	Leaf	R-HSA-74160	Gene expression (Transcription)
R-HSA-2173796	SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription	Leaf	R-HSA-74160	Gene expression (Transcription)
R-HSA-2559580	Oxidative Stress Induced Senescence	Leaf	R-HSA-8953897	Cellular responses to stimuli
R-HSA-2559582	Senescence-Associated Secretory Phenotype (SASP)	Leaf	R-HSA-8953897	Cellular responses to stimuli
R-HSA-2559585	Oncogene Induced Senescence	Leaf	R-HSA-8953897	Cellular responses to stimuli
R-HSA-2871796	FCERI mediated MAPK activation	Leaf	R-HSA-168256	Immune System
R-HSA-3371453	Regulation of HSF1-mediated heat shock response	Leaf	R-HSA-8953897	Cellular responses to stimuli
R-HSA-375165	NCAM signaling for neurite out-growth	Internal node	R-HSA-1266738	Developmental Biology
R-HSA-437239	Recycling pathway of L1	Leaf	R-HSA-1266738	Developmental Biology
R-HSA-444257	RSK activation	Leaf	R-HSA-112316	Neuronal System
R-HSA-445144	Signal transduction by L1	Leaf	R-HSA-1266738	Developmental Biology
R-HSA-450341	Activation of the AP-1 family of transcription factors	Leaf	R-HSA-168256	Immune System
R-HSA-456926	Thrombin signalling through proteinase activated receptors (PARs)	Leaf	R-HSA-109582	Hemostasis
R-HSA-5654726	Negative regulation of FGFR1 signaling	Internal node	R-HSA-162582	Signal Transduction
R-HSA-5654727	Negative regulation of FGFR2 signaling	Internal node	R-HSA-162582	Signal Transduction
R-HSA-5654732	Negative regulation of FGFR3 signaling	Internal node	R-HSA-162582	Signal Transduction
R-HSA-5654733	Negative regulation of FGFR4 signaling	Internal node	R-HSA-162582	Signal Transduction
R-HSA-5663213	RHO GTPases Activate WASPs and WAVEs	Leaf	R-HSA-162582	Signal Transduction
R-HSA-5668599	RHO GTPases Activate NADPH Oxidases	Leaf	R-HSA-162582	Signal Transduction
R-HSA-5673001	RAF/MAP kinase cascade	Internal node	R-HSA-162582	Signal Transduction
R-HSA-5674135	MAP2K and MAPK activation	Leaf	R-HSA-162582	Signal Transduction
R-HSA-5674499	Negative feedback regulation of MAPK pathway	Leaf	R-HSA-162582	Signal Transduction
R-HSA-5675221	Negative regulation of MAPK pathway	Internal node	R-HSA-162582	Signal Transduction
R-HSA-6798695	Neutrophil degranulation	Leaf	R-HSA-168256	Immune System
R-HSA-6802946	Signaling by moderate kinase activity BRAF mutants	Leaf	R-HSA-1643685	Disease
R-HSA-6802948	Signaling by high-kinase activity BRAF mutants	Leaf	R-HSA-1643685	Disease
R-HSA-6802952	Signaling by BRAF and RAF1 fusions	Leaf	R-HSA-1643685	Disease
R-HSA-6802955	Paradoxical activation of RAF signaling by kinase inactive BRAF	Leaf	R-HSA-1643685	Disease
R-HSA-6811558	PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling	Leaf	R-HSA-162582	Signal Transduction
R-HSA-74749	Signal attenuation	Leaf	R-HSA-162582	Signal Transduction
R-HSA-879415	Advanced glycosylation endproduct receptor signaling	Leaf	R-HSA-168256	Immune System
R-HSA-881907	Gastrin-CREB signalling pathway via PKC and MAPK	Internal node	R-HSA-162582	Signal Transduction
R-HSA-8939211	ESR-mediated signaling	Internal node	R-HSA-162582	Signal Transduction
R-HSA-8940973	RUNX2 regulates osteoblast differentiation	Leaf	R-HSA-74160	Gene expression (Transcription)
R-HSA-8943724	Regulation of PTEN gene transcription	Leaf	R-HSA-162582	Signal Transduction
R-HSA-9627069	Regulation of the apoptosome activity	Leaf	R-HSA-5357801	Programmed Cell Death
R-HSA-9634635	Estrogen-stimulated signaling through PRKCZ	Leaf	R-HSA-162582	Signal Transduction
R-HSA-9634638	Estrogen-dependent nuclear events downstream of ESR-membrane signaling	Leaf	R-HSA-162582	Signal Transduction
R-HSA-9635465	Suppression of apoptosis	Leaf	R-HSA-1643685	Disease
R-HSA-9649948	Signaling downstream of RAS mutants	Leaf	R-HSA-1643685	Disease
R-HSA-9652169	Signaling by MAP2K mutants	Leaf	R-HSA-1643685	Disease
R-HSA-9652817	Signaling by MAPK mutants	Leaf	R-HSA-1643685	Disease
R-HSA-9656223	Signaling by RAF1 mutants	Leaf	R-HSA-1643685	Disease
R-HSA-9664422	FCGR3A-mediated phagocytosis	Leaf	R-HSA-1643685	Disease
R-HSA-9725371	Nuclear events stimulated by ALK signaling in cancer	Leaf	R-HSA-1643685	Disease
R-HSA-9768919	NPAS4 regulates expression of target genes	Leaf	R-HSA-74160	Gene expression (Transcription)
R-HSA-982772	Growth hormone receptor signaling	Leaf	R-HSA-168256	Immune System

Subcellular location

Location	ECO term	Pubmed
Cell junction, focal adhesion	ECO:0000250
Cytoplasm	ECO:0000269	PubMed:32721402
Cytoplasm, cytoskeleton, microtubule organizing center, centrosome
Cytoplasm, cytoskeleton, spindle	ECO:0000250
Membrane, caveola	ECO:0000250
Nucleus	ECO:0000269	PubMed:32721402

Interactor | Variant | Drug

Phenotype

HPO ID	HPO name
HP:0000006	Autosomal dominant inheritance
HP:0000010	Recurrent urinary tract infections
HP:0000023	Inguinal hernia
HP:0000028	Cryptorchidism
HP:0000081	Duplicated collecting system
HP:0000154	Wide mouth
HP:0000160	Narrow mouth
HP:0000175	Cleft palate
HP:0000218	High palate
HP:0000219	Thin upper lip vermilion
HP:0000252	Microcephaly
HP:0000272	Malar flattening
HP:0000276	Long face
HP:0000280	Coarse facial features
HP:0000286	Epicanthus
HP:0000307	Pointed chin
HP:0000316	Hypertelorism
HP:0000319	Smooth philtrum
HP:0000324	Facial asymmetry
HP:0000341	Narrow forehead
HP:0000343	Long philtrum
HP:0000347	Micrognathia
HP:0000348	High forehead
HP:0000358	Posteriorly rotated ears
HP:0000363	Abnormal earlobe morphology
HP:0000369	Low-set ears
HP:0000403	Recurrent otitis media
HP:0000407	Sensorineural hearing impairment
HP:0000426	Prominent nasal bridge
HP:0000430	Underdeveloped nasal alae
HP:0000431	Wide nasal bridge
HP:0000453	Choanal atresia
HP:0000463	Anteverted nares
HP:0000465	Webbed neck
HP:0000470	Short neck
HP:0000490	Deeply set eye
HP:0000494	Downslanted palpebral fissures
HP:0000508	Ptosis
HP:0000581	Blepharophimosis
HP:0000635	Blue irides
HP:0000657	Oculomotor apraxia
HP:0000687	Widely spaced teeth
HP:0000691	Microdontia
HP:0000716	Depression
HP:0000718	Aggressive behavior
HP:0000722	Compulsive behaviors
HP:0000739	Anxiety
HP:0000750	Delayed speech and language development
HP:0000957	Cafe-au-lait spot
HP:0000958	Dry skin
HP:0000978	Bruising susceptibility
HP:0000998	Hypertrichosis
HP:0001003	Multiple lentigines
HP:0001004	Lymphedema
HP:0001166	Arachnodactyly
HP:0001182	Tapered finger
HP:0001249	Intellectual disability
HP:0001250	Seizure
HP:0001263	Global developmental delay
HP:0001290	Generalized hypotonia
HP:0001357	Plagiocephaly
HP:0001377	Limited elbow extension
HP:0001388	Joint laxity
HP:0001510	Growth delay
HP:0001511	Intrauterine growth retardation
HP:0001609	Hoarse voice
HP:0001622	Premature birth
HP:0001629	Ventricular septal defect
HP:0001631	Atrial septal defect
HP:0001634	Mitral valve prolapse
HP:0001653	Mitral regurgitation
HP:0001659	Aortic regurgitation
HP:0001660	Truncus arteriosus
HP:0001763	Pes planus
HP:0001770	Toe syndactyly
HP:0001776	Bilateral talipes equinovarus
HP:0001802	Absent toenail
HP:0001817	Absent fingernail
HP:0001840	Metatarsus adductus
HP:0001845	Overlapping toe
HP:0001852	Sandal gap
HP:0002020	Gastroesophageal reflux
HP:0002021	Pyloric stenosis
HP:0002162	Low posterior hairline
HP:0002197	Generalized-onset seizure
HP:0002205	Recurrent respiratory infections
HP:0002230	Generalized hirsutism
HP:0002389	Cavum septum pellucidum
HP:0002463	Language impairment
HP:0002553	Highly arched eyebrow
HP:0002607	Bowel incontinence
HP:0002650	Scoliosis
HP:0002664	Neoplasm
HP:0002673	Coxa valga
HP:0002705	High, narrow palate
HP:0002721	Immunodeficiency
HP:0002967	Cubitus valgus
HP:0003307	Hyperlordosis
HP:0004209	Clinodactyly of the 5th finger
HP:0004279	Short palm
HP:0004322	Short stature
HP:0004942	Aortic aneurysm
HP:0005487	Prominent metopic ridge
HP:0005692	Joint hyperflexibility
HP:0006487	Bowing of the long bones
HP:0007018	Attention deficit hyperactivity disorder
HP:0007874	Almond-shaped palpebral fissure
HP:0009465	Ulnar deviation of finger
HP:0009795	Branchial fistula
HP:0009882	Short distal phalanx of finger
HP:0010296	Ankyloglossia
HP:0010806	U-Shaped upper lip vermilion
HP:0011229	Broad eyebrow
HP:0012168	Head-banging
HP:0012469	Infantile spasms
HP:0025352	Typically de novo
HP:0030084	Clinodactyly
HP:0100033	Tics
HP:0100490	Camptodactyly of finger
HP:0100559	Lower limb asymmetry
HP:0100625	Enlarged thorax

Tissue and cell type

Tissue	Cell type	Expression level	Reliability
adipose tissue	adipocytes	High	Enhanced
adrenal gland	glandular cells	High	Enhanced
appendix	glandular cells	Medium	Enhanced
appendix	lymphoid tissue	Medium	Enhanced
bone marrow	hematopoietic cells	Medium	Enhanced
breast	adipocytes	High	Enhanced
breast	glandular cells	High	Enhanced
breast	myoepithelial cells	High	Enhanced
bronchus	respiratory epithelial cells	High	Enhanced
caudate	glial cells	High	Enhanced
caudate	neuronal cells	High	Enhanced
cerebellum	Purkinje cells	High	Enhanced
cerebellum	cells in granular layer	Medium	Enhanced
cerebellum	cells in molecular layer	Low	Enhanced
cerebral cortex	endothelial cells	Medium	Enhanced
cerebral cortex	glial cells	Medium	Enhanced
cerebral cortex	neuronal cells	High	Enhanced
cerebral cortex	neuropil	High	Enhanced
cervix	glandular cells	High	Enhanced
cervix	squamous epithelial cells	Medium	Enhanced
colon	endothelial cells	High	Enhanced
colon	glandular cells	High	Enhanced
colon	peripheral nerve/ganglion	Medium	Enhanced
duodenum	glandular cells	High	Enhanced
endometrium 1	cells in endometrial stroma	Medium	Enhanced
endometrium 1	glandular cells	Medium	Enhanced
endometrium 2	cells in endometrial stroma	Medium	Enhanced
endometrium 2	glandular cells	Medium	Enhanced
epididymis	glandular cells	Low	Enhanced
esophagus	squamous epithelial cells	Low	Enhanced
fallopian tube	glandular cells	High	Enhanced
gallbladder	glandular cells	Low	Enhanced
heart muscle	cardiomyocytes	Medium	Enhanced
hippocampus	glial cells	High	Enhanced
hippocampus	neuronal cells	High	Enhanced
kidney	cells in glomeruli	Medium	Enhanced
kidney	cells in tubules	Medium	Enhanced
liver	cholangiocytes	Low	Enhanced
liver	hepatocytes	Low	Enhanced
lung	alveolar cells	High	Enhanced
lung	macrophages	High	Enhanced
lymph node	germinal center cells	Medium	Enhanced
lymph node	non-germinal center cells	High	Enhanced
nasopharynx	respiratory epithelial cells	Medium	Enhanced
oral mucosa	squamous epithelial cells	Medium	Enhanced
ovary	follicle cells	Medium	Enhanced
ovary	ovarian stroma cells	Low	Enhanced
pancreas	exocrine glandular cells	High	Enhanced
pancreas	pancreatic endocrine cells	Medium	Enhanced
parathyroid gland	glandular cells	Medium	Enhanced
placenta	decidual cells	Medium	Enhanced
placenta	trophoblastic cells	High	Enhanced
prostate	glandular cells	Medium	Enhanced
rectum	glandular cells	High	Enhanced
salivary gland	glandular cells	Medium	Enhanced
seminal vesicle	glandular cells	Medium	Enhanced
skeletal muscle	myocytes	Medium	Enhanced
skin 1	Langerhans	Medium	Enhanced
skin 1	fibroblasts	Medium	Enhanced
skin 1	keratinocytes	Medium	Enhanced
skin 1	melanocytes	Medium	Enhanced
skin 2	epidermal cells	Medium	Enhanced
small intestine	glandular cells	Low	Enhanced
smooth muscle	smooth muscle cells	Low	Enhanced
soft tissue 1	chondrocytes	Low	Enhanced
soft tissue 1	fibroblasts	High	Enhanced
soft tissue 1	peripheral nerve	Medium	Enhanced
soft tissue 2	fibroblasts	High	Enhanced
soft tissue 2	peripheral nerve	Low	Enhanced
spleen	cells in red pulp	Medium	Enhanced
spleen	cells in white pulp	Medium	Enhanced
stomach 1	glandular cells	Medium	Enhanced
stomach 2	glandular cells	High	Enhanced
testis	Leydig cells	Medium	Enhanced
testis	cells in seminiferous ducts	High	Enhanced
thyroid gland	glandular cells	High	Enhanced
tonsil	germinal center cells	Medium	Enhanced
tonsil	non-germinal center cells	High	Enhanced
tonsil	squamous epithelial cells	Low	Enhanced
urinary bladder	urothelial cells	High	Enhanced
vagina	squamous epithelial cells	High	Enhanced

Disease name	MONDO ID	ICD10	ICD10 chapter	OMIM	Orphanet
heart- malformation of	MONDO:0009327	-	-	OMIM:140500
heart- malformation of	MONDO:0009327	-	-	OMIM:234750
specific learning disability	MONDO:0016225	G00	chapter6, Diseases of the nervous system		Orphanet:211047
specific learning disability	MONDO:0016225	G98	chapter6, Diseases of the nervous system		Orphanet:211047
noonan syndrome 13	MONDO:0033669	Q87	chapter17, Congenital malformations, deformations and chromosomal abnormalities	OMIM:619087

Summary of P28482

Gene: MAPK1, ERK2, PRKM1, PRKM2
Protein: Mitogen-activated protein kinase 1

Structure

GO term

InterPro / Pfam

Reactome

Subcellular location

Interactor | Variant | Drug

Phenotype

Tissue and cell type

Disease

Summary of P28482

Gene: MAPK1, ERK2, PRKM1, PRKM2 Protein: Mitogen-activated protein kinase 1

Structure

GO term

InterPro / Pfam

Reactome

Subcellular location

Interactor | Variant | Drug

Phenotype

Tissue and cell type

Disease

Gene: MAPK1, ERK2, PRKM1, PRKM2
Protein: Mitogen-activated protein kinase 1